<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01694849</url>
  </required_header>
  <id_info>
    <org_study_id>GFT505-212-7</org_study_id>
    <secondary_id>2012-000295-42</secondary_id>
    <nct_id>NCT01694849</nct_id>
  </id_info>
  <brief_title>Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)</brief_title>
  <official_title>A Multicentre, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GFT505 Once Daily on Steatohepatitis in Patients With Non-Alcoholic Steatohepatitis (NASH).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genfit</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Naturalpha</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Premier Research Group plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Genfit</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Abdominal obesity and type-2 Diabetes are associated with chronic liver disorders resulting
      from the accumulation of fat in the liver (steatosis), which may progress towards hepatitis
      and possibly lead to cirrhosis and liver cancer. NAFLD (Non Alcoholic Fatty Liver Disease) is
      considered as the most common form of chronic liver disease in adults in the United States,
      Australia, Asia and Europe. In the USA, the estimated prevalence of NAFLD is 20-30% of the
      adult population.

      Non-alcoholic Steatohepatitis (NASH) is a progressing form of NAFLD, which corresponds to
      hepatic steatosis associated with inflammation and liver cell injury upon microscopic
      examination of a liver biopsy. This condition may lead to advanced fibrosis and cirrhosis and
      deserves serious medical management. Up to now, there is no effective drug which has clearly
      demonstrated therapeutic efficacy which may help lifestyle and dietary recommendations in the
      resolution of NASH.

      In this context, GENFIT is developing a new liver targeted drug candidate, GFT505, for the
      treatment of NASH and the reduction of multiple cardiometabolic risk factors associated with
      the metabolic syndrome and type 2 Diabetes.

      This phase IIb study will evaluate the efficacy and safety of GFT505 80mg and 120mg once
      daily for 52 weeks on the reversal of NASH without worsening of fibrosis, based on liver
      biopsy assessments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study duration per patient will be 80 weeks. A screening period (from 4 to 16 weeks) will
      precede a 52-week double-blind treatment period and a 3 months follow-up period.

      The study will be conducted in 270 patients (90 patients in the placebo arm, 90 patients in
      the GFT505 80mg arm, and 90 patients in the GFT505 120mg arm).

      Enrollment will be performed in two phases: during the first phase, the patients will receive
      either GFT505 at a dose of 80 mg either the placebo. An independent expert committee will
      review the safety data when 45 patients receiving the dose at 80 mg will have been treated
      for 6 months. The committee approval will be necessary to start the second phase, while the
      patients will receive either GFT505 at a dose of 80 mg, or GFT505 at a dose of 120 mg or the
      placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of responders defined by the disappearance of steatohepatitis without worsening of fibrosis</measure>
    <time_frame>52 weeks</time_frame>
    <description>To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the percentage of responders from baseline to Week 52, defined by the disappearance of steatohepatitis (i.e. patients no longer meeting the criteria for steatohepatitis) without worsening of fibrosis.
Worsening of fibrosis is evaluated using NASH CRN (Clinical Research Network) fibrosis staging system and defined as:
Progression to stage 3 or 4 for patients at stage 0, 1 or 2 on diagnostic liver biopsy
Progression to stage 4 for patients at stage 3 on diagnostic liver biopsy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders, defined by the disappearance of steatohepatitis</measure>
    <time_frame>52 weeks</time_frame>
    <description>To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the percentage of responders from baseline to week 52, defined by the disappearance of steatohepatitis (i.e. patients no longer meeting the criteria for steatohepatitis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NAS score (Non-alcoholic fatty liver disease Activity Score)</measure>
    <time_frame>52 weeks</time_frame>
    <description>To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the change from baseline to week 52, in NAS score (Non-alcoholic fatty liver disease Activity Score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stages of steatosis, hepatic activity</measure>
    <time_frame>52 weeks</time_frame>
    <description>To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in stages of steatosis, hepatic activity (lobular inflammation + ballooning).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stages of fibrosis</measure>
    <time_frame>52 weeks</time_frame>
    <description>To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in stages of fibrosis (NASH CRN scoring = Non-Alcoholic Steatohepatitis Clinical Research Network scoring).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area of fibrosis</measure>
    <time_frame>52 weeks</time_frame>
    <description>To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to Week 52, in area of fibrosis by morphometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver enzymes</measure>
    <time_frame>52 weeks</time_frame>
    <description>To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in liver enzymes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-invasive markers of fibrosis and steatosis</measure>
    <time_frame>52 weeks</time_frame>
    <description>To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in non-invasive markers of fibrosis and steatosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid parameters</measure>
    <time_frame>52 weeks</time_frame>
    <description>To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in lipid parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>52 weeks</time_frame>
    <description>To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in body weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>52 weeks</time_frame>
    <description>To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in insulin resistance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>52 weeks</time_frame>
    <description>To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in inflammatory markers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety markers</measure>
    <time_frame>52 weeks</time_frame>
    <description>To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in safety markers (renal or cardiac function parameters).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk profile</measure>
    <time_frame>52 weeks</time_frame>
    <description>To evaluate after 52 weeks of daily administration of GFT505 80mg, or GFT505 120mg, the changes from baseline to week 52, in cardiovascular risk profile.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">270</enrollment>
  <condition>Non-Alcoholic Steatohepatitis (NASH)</condition>
  <arm_group>
    <arm_group_label>GFT505 80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hard gelatin capsules dosed at 40mg, oral administration, 3 capsules per day before breakfast with a glass of water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GFT505 120mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hard gelatin capsules dosed at 40mg, oral administration, 3 capsules per day before breakfast with a glass of water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>hard gelatin capsules, oral administration, 3 capsules per day before breakfast with a glass of water.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GFT505 80mg</intervention_name>
    <arm_group_label>GFT505 80mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GFT505 120mg</intervention_name>
    <arm_group_label>GFT505 120mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females (females must be either of non-child bearing potential or using an
             efficient double contraception). For male participants, contraceptive measures must be
             taken during the study, either by the male participant or his female partner.

          -  Body Mass Index ≤ 45 kg/m².

          -  Patients agree to have one liver biopsy during the screening period for diagnostic
             purpose (if no historical biopsy within 6 months before randomization is available)
             and one at the end of the treatment period for assessment of the treatment effects.

          -  For hypertensive patients, hypertension must be controlled by stable dose of
             anti-hypertensive medication for at least 2 months prior to screening (and the stable
             dose can be maintained throughout the study).

          -  Patients treated with vitamin E (&gt;400IU/d), or Polyunsaturated fatty acids (&gt;2g/day)or
             Ursodeoxycholic acid can be included if drugs are stopped at least 3 months prior to
             diagnostic liver biopsy and up to the end of the study.

          -  Histological confirmation of steatohepatitis on a diagnostic liver biopsy.
             Histological diagnostic is confirmed by central reading of the slides (steatosis &gt; 5%
             + lobular inflammation, any grade + ballooning, any amount).

          -  For patients with Type 2 Diabetes, glycemia must be controlled (Glycosylated
             Haemoglobin A1c ≤8.5%). If glycemia is controlled by anti-diabetic drugs, qualitative
             change is not permitted within 6 months prior to randomization and should be avoided
             during the study. Treatments with metformin, Dipeptidyl Peptidase 4 inhibitors,
             Glucagon-like peptide-1 agonists, sulfamides, insulin are authorized. Sulfamides and
             insulin are permitted if glycemia is self-monitored by the patient.

        Exclusion Criteria:

          -  Known heart failure (Grade I to IV of New York Heart Association classification).

          -  Weight loss of more than 5% within 6 months prior to randomization.

          -  History of bariatric surgery.

          -  Uncontrolled Blood Pressure.

          -  Type 1 diabetes patients.

          -  Patients who had an acute cardiovascular episode within the 6 months prior to
             screening, or with a history of coronary angioplasty, history of stroke, Transient
             Ischemic Attack, Coronary Heart Disease.

          -  Compensated and uncompensated cirrhosis. Notably, NASH patients with fibrosis stage =
             4 according to the NASH CRN fibrosis staging system are excluded.

          -  Known alcohol and/or any other drug abuse or dependence in the last five years.

          -  Pregnant or lactating females.

          -  Other well documented causes of chronic liver disease

          -  Known intolerance or contra-indication to the list of excipients of GFT505.

          -  Evidence of any other unstable or, untreated clinically significant immunological,
             neoplastic, endocrine, haematological, gastrointestinal, neurological or psychiatric
             disorder.

          -  Positive HBsAg (Hepatitis B Surface Antigen), Positive anti-HIV, positive HCV-RNA
             (Hepatitis C Virus).

          -  Uncontrolled hypothyroidism defined as Thyroid Stimulating Hormone &gt; 2X the upper
             limit of normal (ULN). Thyroid dysfunction controlled for at least 6 months prior to
             screening is permitted.

          -  Significant renal disease, including nephritic syndrome, chronic renal failure
             (defined as creatinine clearance &lt; 60 mL/mn and serum creatinine &gt;180 μmol/L).

          -  Unexplained serum creatine phosphokinase (CPK) &gt; 3X the upper limit of normal (ULN).
             Patients with a reason for CPK elevation may have the measurement repeated prior to
             randomization; a CPK retest &gt; 3X ULN leads to exclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rémy HANF, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Development Director Genfit, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pr. Vlad RATZIU, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>International Coordinator - La Pitié-Salpêtrière Hospital - Paris 13, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pr. Arun SANYAL, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Coordinator -Virginia Commonwealth University - Richmond - USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Sven FRANCQUE, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Coordinator - UZA - Edegem - Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Jost PH DRENTH, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Coordinator - UMC St Radboud Nijmegen - Nijmegen - The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pr. Michael Manns, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Coordinator - Medical School of Hannover - Hannover - Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pr. Elisabetha BUGIANESI, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Coordinator - University of Torino - S. Giovanni Battista Hospital - Torino - Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pr. Mihai VOICULESCU, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Coordinator - Center of Internal Medicine, Fundeni Clinical Institute - Bucharest - Romania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pr. Manuel ROMERO-GOMEZ, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Coordinator - Valme University hospital - Sevilla - Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pr. Quentin M. ANSTEE, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Coordinator - Freeman Hospital - Newcastle - UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 920</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>CA 9372</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 903</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>CA 92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 911</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>CO 80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 912</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>FL 32610-0277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 924</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>GA 30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 917</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>GA 30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 909</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>LA 70112-2600</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 921</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>MA 01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 902</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>MI 48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 927</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>NY 10029-6574</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 908</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>NC 27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 919</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>PA 19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 916</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>TN 38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 913</name>
      <address>
        <city>Fort Sam Houston</city>
        <state>Texas</state>
        <zip>TX 78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 923</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>TX 77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 906</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>TX 78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 931</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>UT 84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 930</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>VA 22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 901</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>VA 23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 205</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 201</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 204</name>
      <address>
        <city>Gent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 202</name>
      <address>
        <city>Haine-Saint-Paul</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 203</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 106</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 102</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 114</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 103</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 113</name>
      <address>
        <city>Lyon</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 111</name>
      <address>
        <city>Marseille</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 108</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 104</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 109</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 112</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 101</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 107</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 405</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 404</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 507</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 503</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 504</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 501</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 303</name>
      <address>
        <city>Amsterdam</city>
        <zip>1100</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 302</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 603</name>
      <address>
        <city>Bucharest</city>
        <zip>021105</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 601</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 602</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 703</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 707</name>
      <address>
        <city>Majadahonda</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 705</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 706</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 701</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 802</name>
      <address>
        <city>Camberley</city>
        <zip>GU16 7UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 808</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 801</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 803</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2012</study_first_submitted>
  <study_first_submitted_qc>September 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2012</study_first_posted>
  <last_update_submitted>January 13, 2016</last_update_submitted>
  <last_update_submitted_qc>January 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PPARs</keyword>
  <keyword>NASH</keyword>
  <keyword>Non-Alcoholic Steatohepatitis</keyword>
  <keyword>Liver Diseases</keyword>
  <keyword>Fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

